Joan Danieley - Dec 17, 2021 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Administrative Officer
Signature
/s/ Lyn Amor Macaraeg, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Dec 17, 2021
Transactions value $
-$395,807
Form type
4
Date filed
12/21/2021, 03:01 PM
Previous filing
Dec 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $95.6K +21.5K +395.31% $4.45* 26.9K Dec 17, 2021 Direct F1
transaction AGL Common Stock Sale -$64.3K -2.89K -10.73% $22.27 24K Dec 17, 2021 Direct F1, F2
transaction AGL Common Stock Sale -$427K -18.6K -77.38% $22.97 5.43K Dec 17, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -21.5K -30.05% $0.00 50K Dec 17, 2021 Common Stock 21.5K $4.45 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Joan Danieley is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.64 to $22.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.64 to $23.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 These options were granted on January 31, 2020 and are scheduled to vest in four equal installments on each anniversary of August 13, 2019, subject to continued employment.